Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB
- PMID: 12883336
- DOI: 10.1097/00005344-200308000-00021
Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB
Abstract
The authors investigated the effect of atorvastatin (40 mg qd) on low-density lipoprotein (LDL) particle distribution in patients with dyslipidemias of type IIA (n = 55) and IIB (n = 21). Atorvastatin therapy induced a significant decrease in total and LDL cholesterol in both patient groups. A significant reduction in triglyceride values, which was more profound in type IIB patients, was also observed. In type IIA patients, LDL-3 was the predominant subfraction. Atorvastatin therapy induced a significant reduction in total LDL mass in this group of patients that was mainly due to the reduction in large and intermediate subspecies (LDL-1 to LDL-3), whereas the mass of dense LDL particles (LDL-4 and LDL-5) remained unchanged. As a consequence, the percentage contribution of dense subfractions to the total LDL mass increased significantly after atorvastatin therapy. The dense LDL-4 subfraction was the predominant one in type IIB patients. In this group, atorvastatin therapy resulted in a significant reduction in the total LDL mass, which was due to the reduction in all LDL subfractions. Thus, the percentage mass distribution of LDL particles remained unaffected. These results suggest that the effect of atorvastatin on LDL subfractions is affected by the underlying genetic defect.
Similar articles
-
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.Am J Cardiol. 2001 Jan 1;87(1):44-8. doi: 10.1016/s0002-9149(00)01270-4. Am J Cardiol. 2001. PMID: 11137832 Clinical Trial.
-
Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.Clin Exp Pharmacol Physiol. 2014 Jul;41(7):475-81. doi: 10.1111/1440-1681.12243. Clin Exp Pharmacol Physiol. 2014. PMID: 24739131 Clinical Trial.
-
Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.Exp Clin Endocrinol Diabetes. 2004 May;112(5):241-7. doi: 10.1055/s-2004-817970. Exp Clin Endocrinol Diabetes. 2004. PMID: 15146369 Clinical Trial.
-
The role of small, dense low density lipoprotein (LDL): a new look.Int J Cardiol. 2000 Jun 30;74 Suppl 1:S17-22. doi: 10.1016/s0167-5273(99)00107-2. Int J Cardiol. 2000. PMID: 10856769 Review.
-
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.Ann Pharmacother. 1998 Oct;32(10):1030-43. doi: 10.1345/aph.17231. Ann Pharmacother. 1998. PMID: 9793596 Review.
Cited by
-
Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles.Lipids. 2007 May;42(5):403-9. doi: 10.1007/s11745-007-3050-8. Epub 2007 Apr 11. Lipids. 2007. PMID: 17426995
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials